Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

SNSE/ABBVCL stock hub

SNSE/ABBVCL has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

SNSE/ABBVCLis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

317.5T

Santiago Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

SNSE/ABBVCL

In the news

Latest news · SNSE/ABBVCL

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E13.5

P25 n/aP50 n/aP75 n/a

Trailing P/E95

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC22.8

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All SNSE/ABBVCL market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

192

Groups with data

Currency

USD

Showing 192 of 192 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	CL
Employees	57,000
Employees Change	5,000%
Employees Change Percent	10
Enterprise value	CLP 374.1T
Exchange	Santiago Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	CLP 317.5T
Price	CLP 171,590
Price currency	CLP
Rev Per Employee	1,024,710,140.53x
Sic	2836
Symbol	snse/ABBVCL
Website	https://www.abbvie.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.05%
EV Earnings	111.93x
EV/EBIT	19.18x
EV/EBITDA	13.85x
EV/FCF	20.14x
EV/Sales	6.68x
FCF yield	5.85%
Forward P/E	13.5x
P/B ratio	-51.64x
P/E ratio	94.97x
P/S ratio	5.44x
PE Ratio10 Y	39.99x
PE Ratio3 Y	77.83x
PE Ratio5 Y	56.73x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	34.83%
EBITDA Margin	47.62%
FCF margin	31.81%
Gross margin	72.03%
Gross Profit	CLP 42.1T
Gross Profit Growth	11.06%
Gross Profit Growth Q	15.45%
Gross Profit Growth3 Y	3.97%
Gross Profit Growth5 Y	5.95%
Net Income	CLP 3.3T
Net Income Growth	-13.35%
Net Income Growth Q	-45.96%
Net Income Growth3 Y	-21.86%
Net Income Growth5 Y	-6.73%
Pretax Margin	9.51%
Profit Margin	5.79%
Profit Per Employee	CLP 58.6M
ROA	10.03
Roa5y	8.68
ROCE	23.19
Roe5y	1,295.2
ROIC	22.83
Roic5y	22.84

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	3.72%
EPS Growth	-13.24
EPS Growth Q	-46.25
EPS Growth3 Y	-21.78
EPS Growth5 Y	-6.98
FCF Growth	29.87%
FCF Growth Q	154.57%
FCF Growth3 Y	-5.29%
FCF Growth5 Y	2.35%
OCF Growth	29.41%
OCF Growth Q	134.19%
OCF Growth10 Y	10.14%
OCF Growth3 Y	-4.32%
OCF Growth5 Y	2.62%
Revenue Growth	9.5x
Revenue Growth Q	12.43x
Revenue Growth3 Y	3.45x
Revenue Growth5 Y	4.59x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	CLP 0.46
Assets	CLP 126.9T
Cash	CLP 8.7T
Current Assets	CLP 29.9T
Current Liabilities	CLP 37.5T
Debt	CLP 67.8T
Debt EBITDA	CLP 2.41
Debt FCF	CLP 3.65
Equity	CLP -6.1T
Interest Coverage	7.52
Liabilities	CLP 133T
Long Term Assets	CLP 97T
Long Term Liabilities	CLP 95.5T
Net Cash	CLP -59.1T
Net Cash By Market Cap	CLP -18.6
Net Debt EBITDA	CLP 2.12
Net Debt FCF	CLP 3.18
Tangible Book Value	CLP -86.6T
Tangible Book Value Per Share	CLP -48,996

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.8
Inventory Turnover	3.67
Net Working Capital	CLP -8.9T
Quick ratio	0.52
Working Capital	CLP -8T
Working Capital Turnover	CLP -6,753

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.04%
Dividend Growth	33.58%
Dividend Growth Years	3%
Dividend per share	CLP 6,235
Dividend Years	4
Dividend Yield	3.63%
Ex Div Date	2026-04-15
Last Dividend	CLP 1,534
Payout Frequency	Quarterly
Payout Ratio	325.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	3.72%
200-day SMA	171,590
50-day SMA	171,590
50-day SMA vs 200-day SMA	50under200
All Time High	219,480
All Time High Change	-21.82%
All Time High Date	2025-10-08
All Time Low	165,000
All Time Low Change	3.99%
All Time Low Date	2025-04-21
ATR	105.3
High52	219,480
High52 Date	2025-10-08
High52ch	-21.82%
Low52	171,590
Low52 Date	2026-05-08
Low52ch	0%
Ma50ch	0%
Price vs 200-day SMA	0%
RSI	29.67
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	-0.18x
Total Return	3.59%
Tr YTD	1.81
Tr1m	0.9%
Tr3m	0.9%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	CLP 20.3T
Operating Income Growth	20.85
Operating Income Growth Q	18.82
Operating Income Growth3 Y	0.72
Operating Income Growth5 Y	5.79
Operating margin	34.83

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,763,680,450%
Net Borrowing	2,341,418,830,000
Shares Insiders	0.07%
Shares Institutions	76.02%
Shares Qo Q	0%
Shares Yo Y	0.04%
Short Ratio	3.15

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	CLP 17.7T
Average Volume	0x
Bv Per Share	-3,502.9
CAPEX	CLP -1.2T
Change	0%
Close	171,590
Depreciation Amortization	7,162,406,440,000
Earnings Date	2026-04-29
EBIT	CLP 20.3T
EBITDA	CLP 27.8T
EPS	CLP 1,888
F Score	8
FCF	CLP 18.6T
FCF EV Yield	4.97x
Financing CF	-9,806,495,130,000
Fiscal Year End	December
Founded	2,012
Goodwill	31,703,185,300,000
Income Tax	CLP 2.2T
Investing CF	-6,026,898,780,000
Is Primary Listing	0
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Lynch Fair Value	CLP 9,034
Lynch Upside	-94.74
Ma150	171,590
Ma150ch	0%
Ma20	171,590
Ma20ch	0%
Net CF	3,919,994,640,000
P FCF Ratio	17.09
P OCF Ratio	16.09
Payment Date	2026-05-15
Ppne	5,068,766,230,000
Price Date	2026-05-08
Price EBITDA	CLP 11.41
Relative Volume	2,000x
Revenue	58,408,478,010,000x
SBC By Revenue	1.57x
Share Based Comp	919,562,310,000
Tax By Revenue	3.72x
Tax Rate	39.06%
Tr6m	1.81%
Z Score	2.29

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

SNSE/ABBVCL dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+3.6%

$6235 annual per share

Payout ratio

+325.1%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

3 consecutive years of growth

Total shareholder yield

+3.6%

Next ex-dividend date: 2026-04-15

Performance

SNSE/ABBVCL stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns SNSE/ABBVCL?

Insider, institutional, and short-interest positioning.

Institutional ownership

+76.0%

Share of float held by funds and institutions

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

SNSE/ABBVCL momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

29.7

Below 30: short-term oversold

Price vs 200-day MA

0.0%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.18

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About SNSE/ABBVCL

Hub-level FAQ points readers to the deeper analysis pages.

What is the current snse/ABBVCL stock rating?

snse/ABBVCL is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full snse/ABBVCL analysis?

The full report lives at /stocks/snse/ABBVCL/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for snse/ABBVCL?

The latest report frames snse/ABBVCL around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the snse/ABBVCL page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.